depression

Johnson & Johnson’s Ketamine-Based Drug Treats Depression

SO THEY SAY –

July 22, 2024 – Close to 30 percent of the estimated 280 million people in the world living with major depressive disorder have treatment resistant depression. Sales of Spravato soared 60% to $271 million in the three months ended June 30, compared with the same period in 2023. Spravato has been used by 100,000 people in 77 countries, according to Johnson & Johnson. Spravato is administered as nasal spray and must be taken under the supervision of a healthcare provider in a healthcare setting. Unlike, other antidepressants that regulate chemicals like serotonin and dopamine in the brain, Spravato works by boosting glutamate in the brain. Glutamate is the most abundant neurotransmitter in the brain and helps neurons communicate with each other. 

CONTINUE@Quartz

C Luke

Recent Posts

Archaeologists Uncover Previously Unknown Effect of Tobacco

ALWAYS WITH YOU – Nov. 2, 2024 - Archaeologists have uncovered a previously unknown effect…

7 hours ago

In Tumultuous Times – Readers Turn to ‘Healing Fiction’

TURN OFF CNN – Nov. 7, 2024 - At Toshikazu Kawaguchi’s book signings, it’s not…

7 hours ago

More Layoffs at Addiction Recovery Care Cuts Nearly Quarter of its Workforce

86ed AGAIN? – NOV. 4, 2024 - Two previous rounds of employee cuts in September…

7 hours ago

Winners Foundation Marks 40-Years Helping Racetrack Workers Overcome Alcoholism & Addiction

BY A NOSE – Nov. 5, 2024 - Thoroughbred owner and recovering alcoholic Gino Roncelli…

7 hours ago

Health Issues And Dr. Pepper Addiction

VIDEO – NO VALUE AT ALL – Nov. 4, 2024 - It all started innocently…

7 hours ago

Medicaid Funding Hasn’t Curbed Overdose Deaths

WHAT WOULD? – Nov. 4, 2024 - Stephan Lindner, Ph.D., is lead author on a…

7 hours ago